SHENZHEN NINGYUAN TECHNOLOGY CO., LTD – Trademark Portfolio

Entity Type: 22

SHENZHEN NINGYUAN TECHNOLOGY CO., LTD holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ALLVERNIEA. The owner is based in SHENZHEN CITY.

ROOM 1206B, UNIT 1, FUCHENG TIMES SQUARE, NO. 221, BAOMIN 1ST ROAD, DISTRICT 13, WENHUI COMMUNITY, XIN 'AN SUBDISTRICT, BAO 'AN DISTRICT

SHENZHEN CITY , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

SHENZHEN NINGYUAN TECHNOLOGY CO., LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SHENZHEN NINGYUAN TECHNOLOGY CO., LTD have?

SHENZHEN NINGYUAN TECHNOLOGY CO., LTD has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does SHENZHEN NINGYUAN TECHNOLOGY CO., LTD file in?

SHENZHEN NINGYUAN TECHNOLOGY CO., LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SHENZHEN NINGYUAN TECHNOLOGY CO., LTD's most well-known trademarks?

SHENZHEN NINGYUAN TECHNOLOGY CO., LTD's registered trademark portfolio includes well-known marks such as ALLVERNIEA. These are among 1 currently registered trademark in the portfolio.

What is SHENZHEN NINGYUAN TECHNOLOGY CO., LTD's trademark registration success rate?

SHENZHEN NINGYUAN TECHNOLOGY CO., LTD has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.